When will Entrectinib be launched in China?

Entrectinib (Entrectinib) is a new generation of targeted therapy drugs that belongs to the class of multi-target tyrosine kinase inhibitors (TKI). It is mainly used to treat malignant tumors carrying specific gene mutations, including neuroblastoma carrying NTRK gene fusion, ROS1 gene fusion-positive non-small cell lung cancer (< /span>NSCLC), and ALK gene fusion-positive non-small cell lung cancer (NSCLC), etc.

Enrectinib has been approved by the State Food and Drug Administration of China in 2022 for launch in China. However, due to the short time to market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.

The mechanism of action of this drug is to interfere with the proliferation, division and survival of tumor cells by inhibiting abnormal signaling pathways caused by specific gene mutations in tumor cells. Entrectinib has a multi-target effect and can affect multiple abnormal signaling pathways simultaneously, allowing it to show anti-tumor activity in a variety of tumor types.

Personalized treatment strategies for entrectinib are important because its efficacy is closely related to whether the patient carries a specific gene mutation. Genetic testing is often required before use to determine whether a patient is a candidate for treatment with the drug. This personalized treatment can improve treatment effectiveness and reduce unnecessary side effects.

In short, entrectinib is a drug that targets malignant tumors with specific gene mutations. It has the characteristics of multi-target effects and personalized treatment, and is considered an important progress in the field of tumor treatment.